company background image
SRRK logo

Scholar Rock Holding NasdaqGS:SRRK Stock Report

Last Price

US$15.50

Market Cap

US$1.2b

7D

-0.8%

1Y

74.4%

Updated

29 Feb, 2024

Data

Company Financials +

Scholar Rock Holding Corporation

NasdaqGS:SRRK Stock Report

Market Cap: US$1.2b

SRRK Stock Overview

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.

SRRK fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Scholar Rock Holding Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Scholar Rock Holding
Historical stock prices
Current Share PriceUS$15.50
52 Week HighUS$21.17
52 Week LowUS$5.56
Beta0.90
1 Month Change7.94%
3 Month Change15.24%
1 Year Change74.35%
3 Year Change-69.37%
5 Year Change-2.45%
Change since IPO0%

Recent News & Updates

Scholar Rock: Solid Data And Good Prospects

Jan 12

Recent updates

Scholar Rock: Solid Data And Good Prospects

Jan 12

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Apr 19
Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Oct 20

Jay Backstrom is the new CEO at Scholar Rock

Sep 20

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Jul 12

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

May 21
Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Mar 08
Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be

May 15
Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be

Is Scholar Rock Holding (NASDAQ:SRRK) Using Too Much Debt?

May 07
Is Scholar Rock Holding (NASDAQ:SRRK) Using Too Much Debt?

If You Had Bought Scholar Rock Holding (NASDAQ:SRRK) Stock A Year Ago, You Could Pocket A 283% Gain Today

Mar 01
If You Had Bought Scholar Rock Holding (NASDAQ:SRRK) Stock A Year Ago, You Could Pocket A 283% Gain Today

We Think Scholar Rock Holding (NASDAQ:SRRK) Can Afford To Drive Business Growth

Jan 05
We Think Scholar Rock Holding (NASDAQ:SRRK) Can Afford To Drive Business Growth

Scholar Rock EPS misses by $0.23, misses on revenue

Nov 09

Scholar Rock Is At Phase 2, $1 Billion Is Too Expensive

Nov 04

Scholar Rock prices ~$200M equity offering.

Oct 29

Shareholder Returns

SRRKUS BiotechsUS Market
7D-0.8%1.0%0.4%
1Y74.4%9.2%24.9%

Return vs Industry: SRRK exceeded the US Biotechs industry which returned 11.1% over the past year.

Return vs Market: SRRK exceeded the US Market which returned 25.6% over the past year.

Price Volatility

Is SRRK's price volatile compared to industry and market?
SRRK volatility
SRRK Average Weekly Movement9.7%
Biotechs Industry Average Movement11.9%
Market Average Movement6.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: SRRK's share price has been volatile over the past 3 months.

Volatility Over Time: SRRK's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012114Jay Backstromhttps://scholarrock.com

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia.

Scholar Rock Holding Corporation Fundamentals Summary

How do Scholar Rock Holding's earnings and revenue compare to its market cap?
SRRK fundamental statistics
Market capUS$1.21b
Earnings (TTM)-US$158.92m
Revenue (TTM)n/a

0.0x

P/S Ratio

-7.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SRRK income statement (TTM)
RevenueUS$0
Cost of RevenueUS$115.15m
Gross Profit-US$115.15m
Other ExpensesUS$43.77m
Earnings-US$158.92m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.20
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio29.8%

How did SRRK perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.